Navigation Links
Vasogen Announces First Quarter 2008 Results
Date:4/3/2008

ary 29, November 30,

2008 2007

-------------------------------------------------------------------------

(Unaudited)

Assets

Current assets:

Cash and cash equivalents $ 19,930 $ 23,545

Clinical supplies 1,270 1,363

Tax credits recoverable 738 1,565

Prepaid expenses and deposits 600 787

Change in fair value of forward foreign

exchange contracts - 376

-------------------------------------------------------------------------

22,538 27,636

Property and equipment 352 414

-------------------------------------------------------------------------

$ 22,890 $ 28,050

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Liabilities and Shareholders' Equity

Current liabilities:

Accounts payable $ 1,190 $ 1,175

Accrued liabilities 3,429 3,519

-----------------------------------------------------------------------

4,619 4,694

Shareholders' equity

Share capital:

Authorized:

Unlimited common shares, without par value

Issued and outstanding:

22,391,386 common shares

(November 30, 2007 - 22,391,386) 365,670 365,670

Warrants
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Selexis SA, a serial innovation ... Banks (RCBs) used for drug discovery to commercial manufacturing, ... include Next-Generation Sequencing (NGS) data packages. The ... manufacturing by ensuring the integrity of the gene, validation ...
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, Inc., ... Inc. (NASDAQ: SQNM ), the leading ... for next generation noninvasive prenatal tests (NIPT). Through ... technology, called Mantis™, to advance analysis of clinically-relevant ...
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
(Date:12/24/2014)... YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. ... critical areas, announced the closing of an underwritten public offering ... up to an aggregate 3,500,000 shares of common stock, at ... warrant.  The warrants have a per share exercise price of ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... 2011 Ingenuity® Systems, a leading provider of ... Medical Center, jointly announced a scientific collaboration using ... As part of the collaboration, Erasmus researchers ... the most impactful biological insights from their NGS ...
... 2011 Accuray Incorporated (Nasdaq: ARAY ), a ... it will report results for its second quarter of fiscal ... after the market closes. A conference call to ... ET and will be hosted by Euan S. Thomson, Ph.D., ...
... the world,s leading provider of medical image analysis services ... Dr. Peter Milner has joined SYNARC to expand and ... solutions for the clinical trial setting. Dr. ... brings over 25 years of experience in drug development ...
Cached Biology Technology:Ingenuity Systems and Erasmus University Medical Center Collaborate on Next-Generation Sequencing Project to Accelerate Disease Research 2Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2011 2SYNARC Engages Dr. Peter Milner for Cardiac Imaging Services and Solutions 2
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ...
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this market is ... Chemical sensors help in recording of patient data for ...
(Date:12/11/2014)... blood pressure plays a role in human health has been ... for high blood pressure – was first described as a ... used in measuring blood pressure was invented in 1896. ... its triggers and its effects. In fact, recent findings have ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... rise, some species of corals are likely to succeed at ... on April 12 in the Cell Press journal Current ... effects on corals. "The good news is that, rather ... change by changing the mix of coral species as the ...
... fit frogs have faster-changing genomes, says a new study ... Stretches of DNA accumulate changes over time, but the ... between species, said author Juan C. Santos of the ... In the past, biologists trying to explain why some ...
... cause hearing damage to Sailors and Marines on flight ... funding a new project to help reduce jet noise, ... into two categories: noise exposure on the flight deck ... said Dr. Brenda Henderson, deputy manager for the Jet ...
Cached Biology News:Under climate change, winners and losers on the coral reef 2Athletic frogs have faster-changing genomes 2ONR taps research teams to help reduce jet noise 2
... reports the data from any one of IITC ... recorder. The final data is sent from the ... is automatic for Systolic, Mean, Heart Rate while ... is always in the position to override the ...
... Custom DNA microarrays designed for your specific ... powerful Paraflo microfluidic synthesis platform. Thousands of ... and LC Sciences can provide assistance with ... as part of our comprehensive Custom DNA ...
... RNA aptamer screening and binding optimization and ... microfluidic on-chip synthesis platform. These microarrays are ... Aptamer Microarray Service. Probe Content ... contains greater than 1500 known aptamer sequences. ...
... for RNA aptamer screening and binding optimization ... Paraflo microfluidic on-chip synthesis platform. Thousands of ... on-chip and LC Sciences can provide assistance ... available as part of our comprehensive DNA/RNA ...
Biology Products: